INmune Bio (INMB) vs Serina Therapeutics (SER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
INmune Bio (INMB) has outperformed Serina Therapeutics (SER) over the past year, losing 9.0% versus a loss of 64.3%. Over five years, INMB leads with a -90.2% price change compared with -93.9% for SER. Serina Therapeutics is the larger company by market cap ($51.1 million vs $50.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INMB | SER |
|---|---|---|
| Share price | $1.83 | $2.01 |
| Market cap | $50.79M | $51.05M |
| 1-day change | -1.61% | 0.00% |
| YTD return | +17.31% | +5.07% |
| 1-year return | -8.96% | -64.30% |
| 5-year return | -90.17% | -93.88% |
| EPS (TTM) | $-0.67 | $-1.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.60 | $5.71 |
| 52-week low | $1.09 | $1.22 |
| Distance from 52-week high | -29.62% | -64.80% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +282.51% | +372.64% |
| Average volume | 402.12K | 64.02K |
| Shares outstanding | 27.75M | 25.40M |
| Employees | 21 | 16 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed SER by 55.3 percentage points over the past year.
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Healthcare · Biotechnology · 21 employees
About Serina Therapeutics
SER stock →Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
Healthcare · Biotechnology · 16 employees
INMB vs SER FAQ
Which is bigger, INmune Bio or Serina Therapeutics?
Serina Therapeutics (SER) is larger, with a market capitalization of $51.05M compared with $50.79M for INmune Bio (INMB).
Which stock has performed better over the past year, INMB or SER?
INMB returned -8.96% over the past 12 months, compared with -64.30% for SER (price return, excluding dividends). Past performance does not predict future results.
Are INmune Bio and Serina Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.